ZXZhenhong Xia

Zhenhong Xia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhenhong Xia has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Leonurine (SCM-198) exerts protective effects on pancreatic β-cells in type 1 diabetes by modulating the Bax/Bcl-2/Caspase-3 signaling pathway

    by Zhiqi Li, XiaoRan Liu, FuJiang Wen, WenGuo Jiang, ZhenHong Xia

    Type 1 diabetes mellitus (T1DM) is a disease marked by insulin deficiency and hyperglycemia, resulting from the destruction of pancreatic β-cells. The progression of T1DM is significantly influenced by oxidative stress and apoptosis. Natural compounds are highly effective in the treatment of T1DM and have multiple targets. The natural compound leonurine (SCM-198) possesses anti-inflammatory, anti-oxidant, and anti-apoptotic properties. However, the potential effect of SCM-198 in the treatment of T1DM has not been studied. Our research aims to explore the therapeutic efficacy of SCM-198 in the context of T1DM through the integration of network pharmacology, molecular docking analyses, and both in vitro and in vivo experimental validation. In this study, we used pharmacokinetics to explore the druggability of SCM-198. The mechanisms through which SCM-198 exerts its effects on T1DM were explored using a network pharmacology approach. Subsequently, molecular docking simulations were employed to investigate the binding affinities of the core genes involved in SCM-198 treatment for T1DM. We established a mouse model of streptozotocin (STZ)-induced T1DM in vivo, and evaluated the therapeutic effect of SCM-198 on T1DM by blood glucose measurement, pathology and biochemical analysis, and further formalized the core pathway of SCM-198 regulation using STZ-damaged Min6 cells in vitro. Our findings showed that SCM-198 obeys Lipinski’s rule of five and exhibit desirable absorption, distribution, metabolism excretion and toxicity (ADMET) profiles. The core targets were significantly enriched in the apoptosis pathway. Molecular docking analysis revealed that Cysteine-aspartic Acid Protease 3 (CASP3), Tumor necrosis factor (TNF), and Matrix metallopeptidase 9 (MMP9) exhibited strong binding affinity for SCM-198. In vivo experiments, SCM-198 could not only reduce the fasting blood glucose (FBG), area under the glucose curve, blood lipid, liver function, and oxidative stress level in T1DM model mice, but also effectively improve the histopathological changes of pancreas and aorta. We further demonstrated that SCM-198 could protect Min6 cells from apoptosis by modulating the Bcl-2-associated X Protein (Bax)/B-cell Lymphoma 2 (Bcl-2)/Caspase-3 signaling cascade. The present study demonstrated that SCM-198 exerts a protective effect on pancreatic β-cells in T1DM by attenuating apoptosis through inhibiting the Bax/Bcl-2/Caspase-3 signaling pathway. Therefore, SCM-198 holds great promise as a potential therapeutic candidate for T1DM.


  • Open Access

    Hengtang Capsule Improves Glucose and Lipid Metabolism and Oxidative Stress Levels in Db/db Mice and Underlying Mechanisms

    by Zhi-Qi Li, Xiao-Ran Liu, Wen-Zhuo Ming, Wen-Guo Jiang, Zhen-Hong Xia

    Objectives: Diabetes involves abnormalities in glucolipid metabolism, with oxidative stress serving as a major contributing factor. The Hengtang capsule is a dietary supplement that helps maintain healthy blood glucose (BG) and lipid levels as well as healthy body weight. Given the antioxidative stress effects of various components in the Hengtang capsule, the Hengtang capsule may offer a novel therapeutic approach for treating type 2 diabetes mellitus (T2DM). In this study, we investigated the ability of the Hengtang capsule to treat T2DM through a combination of network pharmacology and animal experiments. Methods: The underlying mechanisms of the Hengtang capsule in treating T2DM were predicted via network pharmacology. After conducting an experiment for 4 weeks, the oral glucose tolerance test (OGTT), fasting blood glucose (FBG), liver function, lipid profile, and oxidative stress markers of the db/db mice were measured. Additionally, the effectiveness of the Hengtang capsule as an antidiabetic agent was assessed via hematoxylin and eosin (HE) staining and immunofluorescence assays. Results: Five core targets, including TP53, AKT1, CTNNB1, STAT3, and EGFR, were identified. The targets were associated mainly with the PI3K/Akt, lipid and atherosclerosis, RAGE/AGE, and FoxO signaling pathways. Additionally, treatment with the Hengtang capsule resulted in significant reductions in the area under the curve (AUC), FBG, total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), aspartate transaminase (AST), alanine transaminase (ALT), and malondialdehyde (MDA) compared to those of the negative control group. In contrast, the concentrations of high-density lipoprotein cholesterol (HDL-C), superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH), and the area occupied by insulin-positive cells increased significantly. Moreover, improvements in liver histopathology were observed. Conclusion: The results showed that the Hengtang capsule may exert therapeutic effects on diabetes by modulating glycolipid metabolism and oxidative stress.

  • Sensitive detection of methimazole based on aggregation-induced delayed electrochemiluminescence active organic dots

    by Shanshan Wu, Xinyu Li, Bijun Wang, Jingshuo Jiang, Di Tao, Zhenhong Xia, Hang Gao, Ningning Wang


  • Open Access

    Resveratrol enhances the antiliver cancer effect of cisplatin by targeting the cell membrane protein PLA2

    by Yu Gao, Zhanyi Yang, Akhilesh Kumar Bajpai, Wenben Wang, Liyuan Zhang, Zhenhong Xia

    Background: In this study, we aimed to explore the mechanism by which resveratrol promotes cisplatin-induced death of HepG2 cells and to provide a potential strategy for resveratrol in the treatment of cancer.Methods: HepG2 cells were exposed to a range of drug concentrations for 24 h: resveratrol (2.5 μg/mL [10.95 μM], 5 μg/mL [21.91 μM], 10 μg/mL [43.81 μM], 20 μg/mL [87.62 μM], 40 μg/mL [175.25 μM], and 80 μg/mL [350.50 μM]), cisplatin (0.625 μg/mL [2.08 μM], 1.25 μg/mL [4.17 μM], 2.5 μg/mL [8.33 μM], 4.5 μg/mL [15.00 μM], and 10 μg/mL [33.33 μM]), 24 μg/mL (105.15 μM) resveratrol + 9 μg/mL (30.00 μM) cisplatin, and 12 μg/mL (52.57 μM) resveratrol + 4.5 μg/mL (15.00 μM) cisplatin. The interaction of two drugs was evaluated by coefficient of drug interaction (CDI), which was based on the Pharmacological Additivity model. The MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay was used to detect the effect of different concentrations of drugs on cell viability, while transcriptome sequencing was used to identify pathways associated with higher gene enrichment. Synchrotron radiation FTIR microspectroscopy experiments and data analysis were conducted to obtain detailed spectral information. The second-derivative spectra were calculated using the Savitzky–Golay algorithm. Single-cell infrared spectral absorption matrices were constructed to analyze the spectral characteristics of individual cells. The Euclidean distance between cells was calculated to assess their spectral similarity. The cell-to-cell Euclidean distance was computed to evaluate the spatial relationships between cells. The target protein of resveratrol was verified by performing a Western blot analysis.Results: After 24 h of treatment with resveratrol, HepG2 cell growth was inhibited in a dose-dependent manner. Resveratrol promotes cisplatin-induced HepG2 cell death through membrane-related pathways. It also significantly changes the membrane components of HepG2 cells. Additionally, resveratrol changes the morphology of the HepG2 cell membrane by decreasing the expression of PLA2G2.Conclusion: Resveratrol changes the morphology of the HepG2 cell membrane by decreasing the expression of PLA2G2 and promotes cisplatin-induced HepG2 cell death. The combination of cisplatin and resveratrol can play a synergistic therapeutic effect on HepG2 cells.


  • Open Access

    Isobavachalcone Inhibits Hyperglycemia and Hyperlipemia in Type 2 Diabetes and the Underlying Mechanisms

    by Zhenhong Xia, Xiaoran Liu, Yuqi Li, Zhiqi Li, Feixue Ni, Geng Tian, Wenguo Jiang

    Objective: The aim of this research was to probe the effect of isobavachalcone inhibiting the high-fat diet (HFD) and streptozotocin (STZ) induced hyperglycemia and hyperlipemia in mice and its underlying mechanisms. Methods: A mouse model with type 2 diabetes mellitus (T2DM) was established by the HFD and low-dose streptozotocin. T2DM mice were treated with 10 mg/kg of isobavachalcone for 4 weeks. The levels of fasting blood glucose (FBG), blood lipids, and relative proteins in the PI3K/AKT signaling pathway as well as the histological structural changes in the liver were determined. Results: The results showed that the expression levels of FBG (42%, P < .001), triglyceride (70%, P < .001), and glucose transporter 2 were significantly reduced by isobavachalcone. The proteinic and mRNA expressions of IRS1, PI3K, and AKT genes of T2DM mice were dramatically increased with the isobavachalcone treatment. Furthermore, isobavachalcone ameliorated the morphology of the liver in T2DM model mice. Conclusion: The results suggested that isobavachalcone controls the development of T2DM as well as the regulatory mechanism involved in glucose and lipid metabolism through the PI3K/AKT signal pathway in the liver.